SynthesisThe Journal of clinical endocrinology and metabolism2026
Systematic mapping and in silico reevaluation of genomic copy number variations in primary ovarian insufficiency.
Synthesis in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Systematic mapping and in silico reevaluation of genomic copy number variations in primary ovarian insufficiency.The Journal of clinical endocrinology and metabolism · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary ovarian insufficiency (POI) is a highly heterogeneous condition characterized by the cessation of ovarian function before age 40. While genetic factors play a substantial role, the contribution of structural variants remains incompletely mapped. We conducted a systematic review and in silico genomic re-analysis of published copy number variations (CNVs) in individuals with POI. Following PRISMA guidelines, we aggregated 382 CNVs from 25 studies, standardized genomic coordinates, and filtered variants against population databases. Pathogenicity was reevaluated using ACMG/ClinGen guidelines, yielding 42 pathogenic/likely pathogenic variants and 25 large CNVs (>3.5 Mb). Consistent with previous findings, the X chromosome exhibited the highest CNV burden, emphasizing its central role in structural genomic instability and POI pathogenesis. Beyond canonical POI-associated genes, gene ontology and GTEx expression profiling identified several biologically plausible, highly ovary-expressed candidate genes within disrupted loci-notably ATF3, GAS5, PPP4R1, and PRKAA1. Despite their established roles in cellular stress responses, DNA repair, and meiotic progression, these genes remain absent from most commercial POI diagnostic panels. This comprehensive re-analysis highlights the complex structural genomic landscape of POI and suggests that expanding current clinical testing panels to include these under-recognized genes could improve diagnostic yields for genetically unexplained cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.